(Q38860651)

English

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 September 2017

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma (English)

1 reference

Europe PubMed Central

7 September 2017

0 references

Annegien Broeks

5

object named as

Annegien Broeks

1 reference

Europe PubMed Central

7 September 2017

Ekaterina S. Jordanova

4

object named as

Ekaterina S Jordanova

1 reference

Europe PubMed Central

7 September 2017

Tanja D de Gruijl

8

object named as

Tanja D de Gruijl

1 reference

Europe PubMed Central

7 September 2017

Christian U Blank

11

object named as

Christian U Blank

1 reference

Europe PubMed Central

7 September 2017

John B A G Haanen

9

object named as

John B A G Haanen

1 reference

Europe PubMed Central

7 September 2017

author name string

Aurelie Guislain

1

1 reference

Europe PubMed Central

7 September 2017

Jules Gadiot

2

1 reference

Europe PubMed Central

7 September 2017

Andrew Kaiser

3

1 reference

Europe PubMed Central

7 September 2017

Joyce Sanders

6

1 reference

Europe PubMed Central

7 September 2017

Hester van Boven

7

1 reference

Europe PubMed Central

7 September 2017

Axel Bex

10

1 reference

Europe PubMed Central

7 September 2017

publication date

24 June 2015

1 reference

Europe PubMed Central

7 September 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

7 September 2017

64

1 reference

Europe PubMed Central

7 September 2017

10

1 reference

Europe PubMed Central

7 September 2017

1241-1250

1 reference

Europe PubMed Central

7 September 2017

https://scigraph.springernature.com/pub.10.1007/s00262-015-1735-z

0 references

Targeted therapy for advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Adoptive cell therapy for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Deciphering signatures of mutational processes operative in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

The cancer antigenome

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

TCR repertoires of intratumoral T-cell subsets

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1735-Z

21 January 2018

Identifiers

10.1007/S00262-015-1735-Z

1 reference

Europe PubMed Central

7 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38860651&oldid=2142063622"